Alpha cognition incACOG.US Overview

US StockHealthcare

(No presentation for ACOG)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ACOG Overall Performance

ACOG AI Analysis & Strategy

ACOG Recent Performance

-2.88%

Alpha cognition inc

0.81%

Avg of Sector

-1.14%

S&P500

ACOG PowerScanner

ACOG Key Information

ACOG Valuation Metrics

ACOG Earnings Table

ACOG Profile

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.